Brian S Kim1, Roy Vongtama, Guy Juillard. 1. Department of Radiation Oncology, University of California at Los Angeles, UCLA Medical Center, USA. bkim@mednet.ucla.edu
Abstract
PURPOSE: The purpose of this study was to understand the natural history and progression of sinonasal undifferentiated carcinoma (SNUC) to establish optimal management guidelines. Methods and materials We analyzed 8 consecutively treated patients diagnosed with SNUC between 1995 and 2002 at UCLA Medical Center. Staging was classified by the Kadish System with 7 patients presenting at stage C and 1 patient with stage B disease. Five patients received surgery. Four of these 5 patients received adjuvant radiotherapy, with 2 patients receiving it concurrently with chemotherapy (cisplatinum/5-fluorouracil). One patient received surgery alone as definitive management. Of the remaining 3 patients who did not receive surgical treatment, concurrent chemotherapy and radiation was used. RESULTS: At last follow-up, 6 of the 8 patients were still alive (overall survival 75%) with mean survival time of 20.6 months. However, only 2 of the 6 were alive and free of disease (disease-free survival 25%) with a mean disease-free survival time of 12.3 months. Locoregional recurrence occurred in 5 of the 8 patients (63%). Time to recurrence ranged from 3 to 30 months. Distant metastasis presented in 4 of the 8 patients (50%), all with disease spread to bone. Two of the 4 patients with distant metastasis were found to have locoregional disease recurrence at the same time. Time to metastasis ranged from 2 to 30 months. Results also show that the 5 patients who received surgery are still alive with a mean survival time of 23 months at last follow-up. Meanwhile, 1 of the 3 patients who received no surgical therapy is alive, with a mean survival time of 16.7 months in this group. CONCLUSIONS: SNUC has proven to have a poor prognosis. Although limited by small numbers, this study along with reported series in the past appear to suggest longer survival results with aggressive multimodality therapy, especially with the incorporation of complete surgical resection.
PURPOSE: The purpose of this study was to understand the natural history and progression of sinonasal undifferentiated carcinoma (SNUC) to establish optimal management guidelines. Methods and materials We analyzed 8 consecutively treated patients diagnosed with SNUC between 1995 and 2002 at UCLA Medical Center. Staging was classified by the Kadish System with 7 patients presenting at stage C and 1 patient with stage B disease. Five patients received surgery. Four of these 5 patients received adjuvant radiotherapy, with 2 patients receiving it concurrently with chemotherapy (cisplatinum/5-fluorouracil). One patient received surgery alone as definitive management. Of the remaining 3 patients who did not receive surgical treatment, concurrent chemotherapy and radiation was used. RESULTS: At last follow-up, 6 of the 8 patients were still alive (overall survival 75%) with mean survival time of 20.6 months. However, only 2 of the 6 were alive and free of disease (disease-free survival 25%) with a mean disease-free survival time of 12.3 months. Locoregional recurrence occurred in 5 of the 8 patients (63%). Time to recurrence ranged from 3 to 30 months. Distant metastasis presented in 4 of the 8 patients (50%), all with disease spread to bone. Two of the 4 patients with distant metastasis were found to have locoregional disease recurrence at the same time. Time to metastasis ranged from 2 to 30 months. Results also show that the 5 patients who received surgery are still alive with a mean survival time of 23 months at last follow-up. Meanwhile, 1 of the 3 patients who received no surgical therapy is alive, with a mean survival time of 16.7 months in this group. CONCLUSIONS: SNUC has proven to have a poor prognosis. Although limited by small numbers, this study along with reported series in the past appear to suggest longer survival results with aggressive multimodality therapy, especially with the incorporation of complete surgical resection.
Authors: Kyle J Chambers; Ashton E Lehmann; Aaron Remenschneider; Matthew Dedmon; Josh Meier; Stacey T Gray; Derrick T Lin Journal: J Neurol Surg B Skull Base Date: 2014-09-29
Authors: Alan D Workman; Robert M Brody; Edward C Kuan; Esther Baranov; Steven G Brooks; Michelle Alonso-Basanta; Jason G Newman; Christopher H Rassekh; Ara A Chalian; Alexander G Chiu; Gregory S Weinstein; Michael D Feldman; Nithin D Adappa; Bert W O'Malley; James N Palmer Journal: J Neurol Surg B Skull Base Date: 2018-08-16
Authors: Tom P van der Laan; Hendrik P Bij; Bettien M van Hemel; Boudewijn E C Plaat; Jan Wedman; Bernard F A M van der Laan; Gyorgy B Halmos Journal: Eur Arch Otorhinolaryngol Date: 2013-06-06 Impact factor: 2.503
Authors: Moran Amit; Ahmed S Abdelmeguid; Teemaranawich Watcherporn; Hideaki Takahashi; Samantha Tam; Diana Bell; Renata Ferrarotto; Bonnie Glisson; Michael E Kupferman; Dianna B Roberts; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna Journal: J Clin Oncol Date: 2019-01-07 Impact factor: 44.544
Authors: Erin M Lin; Anthony Sparano; Aaron Spalding; Avraham Eisbruch; Francis P Worden; Jason Heth; Stephen E Sullivan; B Gregory Thompson; Lawrence J Marentette Journal: Skull Base Date: 2010-03
Authors: João Adolfo Costa Hanemann; Marina Lara de Carli; Ernesto Rabello Dendena; Carlos Eduardo Gomes do Couto Filho; Suzana Catanhede Orsini Machado de Sousa; Alessandro Antônio Costa Pereira; Fernanda Salgueiredo Giudice; Felipe Fornias Sperandio Journal: Oral Maxillofac Surg Date: 2017-10-25
Authors: Peter H Ahn; Nandita Mitra; Michelle Alonso-Basanta; Nithin D Adappa; James N Palmer; Bert W O'Malley; Christopher H Rassekh; Ara Chalian; Roger B Cohen; Alexander Lin Journal: Br J Radiol Date: 2015-11-11 Impact factor: 3.039